Learn more about the application of contextual tissue biomarkers to drive clinical decision making at booth #1553
March 7, 2017 – Westminster, CO – Flagship Biosciences, the pioneer of Computational Tissue Analysis, is pleased to announce that it will present posters and exhibit at the American Association for Cancer Research (AACR) Annual Meeting, April 1-5, 2017, in Washington, D.C. AACR’s annual meeting, @AACR, highlights the best cancer science and medicine from institutions all over the world. Flagship is committed to the advancement of the field of immuno-oncology, as reflected by the numerous scientific posters being presented at the conference.
Visit Flagship at booth #1553 and the following poster presentations to learn about how Flagship is contributing to immune-oncology research and clinical trial success through the application of the company’s Computational Tissue Analysis (cTA™) platform and decision support process. cTA™ uses tissue based biomarkers to accelerate drug development with confident, data-driven decisions.
Posters presented by Flagship scientists include:
1. Poster: Analytical Validation of Ki67/CD8 Duplex IHC Assay Using Computational Tissue Analysis (cTA™)
- Abstract #763
- Time: Sunday, April 2nd, 1:00pm – 5:00pm
- Location: Section 31, Board 29
- Category: Clinical Research
- Presenter: Staci Kearney, PhD, RAC; Associate Director of Clinical and Regulatory Affairs
2. Poster: Evaluating “Harmonization” of PD-L1 Assays Using Image Analysis
- Abstract #661
- Time: Sunday, April 2nd, 1:00pm – 5:00pm
- Location: Section 28, Board 7
- Category: Clinical Research
- Presenter: Carsten Schnatwinkel, PhD; Biomedical Science Liaison
3. Poster: Providing Confidence Around Computational Tissue Analysis Using Heterogeneity Assessments
- Abstract #1710
- Time: Monday, April 3rd, 8:00am – 12:00pm
- Location: Section 29, Board 29 - Category: Clinical Research
- Presenter: Carsten Schnatwinkel, PhD; Biomedical Science Liaison
4. Poster: Quantifying Tumor-Infiltrating Immune Cells in Isotype Antibody Stained NSCLC Samples using Morphometric Features
- Abstract #1674
- Time: Monday, April 3rd, 8:00am – 12:00p,
- Location: Section 28, Board 22
- Category: Immunology
- Presenter: Allison Harney, PhD; Scientist II
5. Poster: Evaluating Benefits of PD-L1 Image Analysis for the Clinical Setting
- Abstract #4582 - Time: Tuesday, April 4th, 1:00pm – 5:00pm
- Location: Section 25, Board 27
- Category: Immunology
For a quick reference guide to Flagship at AACR, click this link: AACR Quickguide
If you would like to schedule a meeting with Flagship’s scientists or representatives during the meeting, please email info@flagshipbio.com
Follow Flagship on Twitter @flagshipbio for AACR updates and news.
About Flagship Biosciences
Flagship Biosciences helps drug developers confidently define their path to success. By leveraging our unique computational Tissue Analysis (cTA™) and Data-Driven-Decision Support Platform, we provide quantitative and contextual tissue interpretation to make timely decisions. Flagship is proud to have served over 100 pharmaceutical and biotech companies.
For more information on how Flagship accelerates drug development, please visit the Company’s website: www.flagshipbio.com.
March 7, 2017 – Westminster, CO – Flagship Biosciences, the pioneer of Computational Tissue Analysis, is pleased to announce that it will present posters and exhibit at the American Association for Cancer Research (AACR) Annual Meeting, April 1-5, 2017, in Washington, D.C. AACR’s annual meeting, @AACR, highlights the best cancer science and medicine from institutions all over the world. Flagship is committed to the advancement of the field of immuno-oncology, as reflected by the numerous scientific posters being presented at the conference.
Visit Flagship at booth #1553 and the following poster presentations to learn about how Flagship is contributing to immune-oncology research and clinical trial success through the application of the company’s Computational Tissue Analysis (cTA™) platform and decision support process. cTA™ uses tissue based biomarkers to accelerate drug development with confident, data-driven decisions.
Posters presented by Flagship scientists include:
1. Poster: Analytical Validation of Ki67/CD8 Duplex IHC Assay Using Computational Tissue Analysis (cTA™)
- Abstract #763
- Time: Sunday, April 2nd, 1:00pm – 5:00pm
- Location: Section 31, Board 29
- Category: Clinical Research
- Presenter: Staci Kearney, PhD, RAC; Associate Director of Clinical and Regulatory Affairs
2. Poster: Evaluating “Harmonization” of PD-L1 Assays Using Image Analysis
- Abstract #661
- Time: Sunday, April 2nd, 1:00pm – 5:00pm
- Location: Section 28, Board 7
- Category: Clinical Research
- Presenter: Carsten Schnatwinkel, PhD; Biomedical Science Liaison
3. Poster: Providing Confidence Around Computational Tissue Analysis Using Heterogeneity Assessments
- Abstract #1710
- Time: Monday, April 3rd, 8:00am – 12:00pm
- Location: Section 29, Board 29 - Category: Clinical Research
- Presenter: Carsten Schnatwinkel, PhD; Biomedical Science Liaison
4. Poster: Quantifying Tumor-Infiltrating Immune Cells in Isotype Antibody Stained NSCLC Samples using Morphometric Features
- Abstract #1674
- Time: Monday, April 3rd, 8:00am – 12:00p,
- Location: Section 28, Board 22
- Category: Immunology
- Presenter: Allison Harney, PhD; Scientist II
5. Poster: Evaluating Benefits of PD-L1 Image Analysis for the Clinical Setting
- Abstract #4582 - Time: Tuesday, April 4th, 1:00pm – 5:00pm
- Location: Section 25, Board 27
- Category: Immunology
For a quick reference guide to Flagship at AACR, click this link: AACR Quickguide
If you would like to schedule a meeting with Flagship’s scientists or representatives during the meeting, please email info@flagshipbio.com
Follow Flagship on Twitter @flagshipbio for AACR updates and news.
About Flagship Biosciences
Flagship Biosciences helps drug developers confidently define their path to success. By leveraging our unique computational Tissue Analysis (cTA™) and Data-Driven-Decision Support Platform, we provide quantitative and contextual tissue interpretation to make timely decisions. Flagship is proud to have served over 100 pharmaceutical and biotech companies.
For more information on how Flagship accelerates drug development, please visit the Company’s website: www.flagshipbio.com.
